Ocrelizumab: a step forward in the evolution of B-cell therapy - Wikidata - wikimedia - TriplyDB

Ocrelizumab: a step forward in the evolution of B-cell therapy

Ocrelizumab: a step forward in the evolution of B-cell therapy

http://www.wikidata.org/entity/Q28245986

about

New and emerging disease modifying therapies for multiple sclerosis Rheumatologic manifestations of sarcoidosis B Cells Are Multifunctional Players in Multiple Sclerosis Pathogenesis: Insights from Therapeutic Interventions Musculoskeletal involvement in sarcoidosis CD19 as a molecular target in CNS autoimmunity.Treating multiple sclerosis with monoclonal antibodies: a 2010 update.New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies.Update on novel monoclonal antibodies and immunoconjugates for the treatment of lymphoproliferative disorders.Emerging disease-modifying therapies in multiple sclerosis.Targeted drug delivery for cancer therapy: the other side of antibodies.Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia.The problem of choice: current biologic agents and future prospects in RA.Monoclonal antibodies in neuroinflammatory diseases.B-cell targeted therapeutics in clinical development.Drugs in development for relapsing multiple sclerosis.Drugs in clinical development for multiple sclerosis: focusing on anti-CD20 antibodies.Monoclonal antibodies in treatment of multiple sclerosis.Recent developments in the treatment of patients with systemic lupus erythematosus: focusing on biologic therapies.Clinical management of multiple sclerosis and neuromyelitis optica with therapeutic monoclonal antibodies: approved therapies and emerging candidates.Monoclonal antibody therapy in multiple sclerosis: critical appraisal and new perspectives.Monoclonal antibodies for renal diseases: current concepts and ongoing treatments.Safety and efficacy of ocrelizumab in rheumatoid arthritis patients with an inadequate response to methotrexate or tumor necrosis factor inhibitors: a systematic review and meta-analysis.Myeloid cells - targets of medication in multiple sclerosis.B-cell-targeted therapies in relapsing forms of MS.Antibodies in Phase III Studies for Immunological Disorders

P2860

Q22242305-FDA536B2-673D-4AB9-8E73-46D92F93CFB8 Q24608644-412A62FD-663E-49A0-A8B3-545FAE489969 Q26770664-BB7A68FA-03B2-4634-BE86-DD6352A083BF Q33852438-C2C65E52-0306-4A07-8D0E-B6CA1692A75F Q34976749-6722438D-47D6-466D-86C5-7302B1BB2757 Q37737305-AF20D9DD-805F-47FD-AF62-B07C4F2D75B3 Q37810901-BB95896D-BC92-499A-A4BA-EE520C1E182F Q37913356-115BF9B1-EC33-4A7B-A352-591322EB97C8 Q37994555-7BF00276-9C54-4AFA-B434-9F78174CAA1D Q38058816-B4D634AC-7452-4D75-9CC0-3F01904E0B70 Q38068494-D5C80CEA-6C0F-4CC3-9556-90EF1201EA72 Q38082588-6D583F11-4A7A-4B07-B208-40746DDD942E Q38092121-C72DE6CF-335C-473D-B096-0791B950B329 Q38097162-B75DD4DB-351E-4270-B579-AE1B979D97B2 Q38101004-BE3CF853-9646-4677-B3CC-D94B5A3FEDE5 Q38121632-AD1FD7D1-22F2-402B-B5B3-EA2E2E40D984 Q38133865-B8F87464-53CD-46FC-9C01-298B6ECFA00A Q38175493-41B38A54-29B8-4E82-B1D9-D195D7F470C7 Q38286209-C1D283E2-1A0A-47AE-9836-7F80A93BA10F Q38364547-0245BB47-6918-493F-BCB1-D63FD96A0009 Q38531349-D76B8481-901C-43EF-9A59-4DE914808A91 Q38753455-633116F5-F5C0-46F9-910F-733C6A757983 Q38924828-D8F5CB53-CADE-44F9-8049-09E560AC4E9E Q42631407-2B72E1DE-26D7-4580-837B-6415E79D1119 Q58874863-966A1F18-BCEB-42A4-8610-401B55F8058E

P2860

Ocrelizumab: a step forward in the evolution of B-cell therapy

http://www.wikidata.org/entity/Q28245986

description

2009 nî lūn-bûn

@nan

2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Ocrelizumab: a step forward in the evolution of B-cell therapy

@ast

Ocrelizumab: a step forward in the evolution of B-cell therapy

@en

Ocrelizumab: a step forward in the evolution of B-cell therapy

@nl

type

label

Ocrelizumab: a step forward in the evolution of B-cell therapy

@ast

Ocrelizumab: a step forward in the evolution of B-cell therapy

@en

Ocrelizumab: a step forward in the evolution of B-cell therapy

@nl

prefLabel

Ocrelizumab: a step forward in the evolution of B-cell therapy

@ast

Ocrelizumab: a step forward in the evolution of B-cell therapy

@en

Ocrelizumab: a step forward in the evolution of B-cell therapy

@nl

P1433

Q28245986-DC728070-2430-47EE-ACCB-D93B5D78D5F8

P1476

Q28245986-C841B9A0-9598-405C-9DE5-B549EA827858

P2093

Q28245986-013026F4-618E-462F-A5BB-8FC135EFFC30

Q28245986-09C61EE3-E250-4BF6-B778-58DA0919BD23

Q28245986-1555DEB3-E4DC-48C4-AB0A-D8837F324EE6

Q28245986-3265C6A5-2E22-4C3B-9E3F-1D76FA9648FB

Q28245986-3ECA1EC6-1F8F-454B-BB16-1379A7D7751C

Q28245986-3F9948A0-DBBD-4E63-8FE5-7C6B7FCB27D3

Q28245986-6F4BEF06-38D5-4A74-8579-DEFA0EB0AF56

Q28245986-AF506170-2482-4305-B929-00D1B9B1DB81

P2860

Q28245986-05515033-A887-4D78-9C6A-5248495E15EC

Q28245986-0C9F95C3-DE73-418B-85BC-29E8B0226A9E

Q28245986-0CAE0866-6E40-49EB-865E-D81B357D60DF

Q28245986-173ED229-FB5D-4D65-BCBD-D261B85458C5

Q28245986-46FFB35C-AA71-4A73-B40F-63FFA09DA3C6

Q28245986-5B9F932A-5DE1-492C-8BC2-4135891A27EC

Q28245986-5BD4ECE0-631A-46D8-B50C-416336A9FE96

Q28245986-9AC78886-8AAF-4289-9249-83B2915C02CA

Q28245986-A1A53EF7-7422-4D8A-B167-5EF69D1DCC4B

Q28245986-AAA8D8B0-1D18-46CD-A468-CD89025EC02A

P304

Q28245986-5F39A347-39F4-4AF8-BA14-E85BEF675581

P31

Q28245986-C4D4E52E-FAFE-4ECB-B676-266E4CE75866

P356

Q28245986-6AF62165-FE07-4C13-8A09-4299692E692C

P407

Q28245986-2FC7E6DB-60B9-45E4-B0A1-355ABFD22494

P433

Q28245986-81A2E6D8-935E-40AA-BC39-786B77C0E152

P478

Q28245986-C2B978C1-4214-41C4-A475-4DB70383E75A

P50

Q28245986-626E9352-F6D9-478C-92E5-DDA662ABF6E6

P577

Q28245986-C232DF16-A7BD-4781-A5F5-C350BDEFAB86

P698

Q28245986-C3B98FFD-E5D4-4448-9B89-097EAD124413

P356

14712590903018837

P1433

Expert Opinion on Biological Therapy

P1476

Ocrelizumab: a step forward in the evolution of B-cell therapy

@en

P2093

Fariha Kausar

http://www.w3.org/2001/XMLSchema#string

Ghaleb Sweis

http://www.w3.org/2001/XMLSchema#string

Khader Mustafa

http://www.w3.org/2001/XMLSchema#string

Khaldoon Alawneh

http://www.w3.org/2001/XMLSchema#string

Maria Badaracco

http://www.w3.org/2001/XMLSchema#string

Nadera J Sweiss

http://www.w3.org/2001/XMLSchema#string

Rafah Salloum

http://www.w3.org/2001/XMLSchema#string

Ray Sawaqed

http://www.w3.org/2001/XMLSchema#string

P2860

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.

Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin.

First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial.

Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumati

Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus

Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study

Inherent specificities in natural antibodies: a key to immune defense against pathogen invasion.

P304

889-95

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14712590903018837

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

Timothy B. Niewold

P577

2009-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19463076

http://www.w3.org/2001/XMLSchema#string